Dantrolene RyR2 Stabilization for Arrhythmia Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cardiac arrhythmias, particularly ventricular tachycardia and ventricular fibrillation, have limited success in improving survival and hemodynamic outcomes, with existing therapies failing to effectively address the underlying ion channel dysfunctions and calcium overload issues that contribute to these life-threatening conditions.
Innovation Solution
Administration of dantrolene or its derivatives, which stabilize the cardiac-specific Ryanodine Receptor 2 (RyR2), thereby reducing calcium leak and hyperphosphorylation, and are used in conjunction with anti-arrhythmic agents to treat and prevent cardiac arrhythmias, including those occurring post-cardiac arrest, improving return of spontaneous circulation and reducing morbidity and mortality.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional anti-arrhythmic therapies are used, then some arrhythmia symptoms may be temporarily managed, but survival rates and hemodynamic outcomes remain poor due to inability to address underlying ion channel dysfunctions and calcium overload
Solution Approach 1:
The patent changes the therapeutic parameter from conventional anti-arrhythmic agents to dantrolene, a Ryanodine Receptor modulator. This parameter change targets the root cause of arrhythmias by stabilizing RyR2 and preventing calcium leak, thereby improving survival rates and hemodynamic outcomes without compromising treatment feasibility
Solution Approach 2:
Dantrolene acts as an intermediary substance that mediates between the dysregulated calcium release channels (RyR2) and the pathological arrhythmia outcomes. By binding to RyR2 and stabilizing its closed state, dantrolene interrupts the pathological calcium cycling that leads to arrhythmias, improving reliability without complicating treatment administration
2Reliability
If existing therapies are applied, then immediate symptom management is attempted, but they fail to effectively address underlying ion channel dysfunctions and calcium overload issues
Solution Approach 1:
The patent extracts and targets the specific pathological mechanism of RyR2 dysfunction and calcium leak from the complex arrhythmia pathology. By focusing therapy specifically on stabilizing RyR2 calcium release channels, the treatment addresses the root cause (ion channel dysfunction) rather than just managing symptoms, thereby improving efficacy without requiring complex multi-target interventions
Solution Approach 2:
The invention changes the therapeutic mechanism parameter from conventional anti-arrhythmic approaches to direct RyR2 modulation. This parameter change simplifies the treatment mechanism by targeting a single critical dysfunction (calcium leak through dysregulated RyR2) rather than attempting to manage multiple complex pathways simultaneously, improving efficacy while maintaining mechanistic clarity
3Reliability
If dantrolene is administered to stabilize RyR2 and reduce calcium leak, then defibrillation success improves and refibrillations are reduced, but the complexity of treatment protocol increases
Solution Approach 1:
Dantrolene is administered as a preliminary action before defibrillation to pre-stabilize RyR2 channels and reduce calcium leak. This preliminary stabilization of calcium handling mechanisms improves defibrillation success by creating a more favorable electrophysiological substrate, while the drug's single-dose administration keeps the protocol relatively simple
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Dantrolene treatment significantly improves defibrillation success, reduces refibrillations, and enhances cardiac contractility, leading to improved survival rates and hemodynamic stability by stabilizing RyR2 and mitigating calcium alternans and hyperphosphorylation, thus addressing the root causes of ventricular arrhythmias.
Implementation Method 1
dantrolene, derivatives or analogs thereof, are effective for the acute treatment of cardiac arrhythmias... stabilize the cardiac-specific Ryanodine Receptor 2 (RyR2), thereby reducing calcium leak and hyperphosphorylation
Data Source
Figure 1(A)~1(B)
Figure 2
Figure 3
AI summary
The present description relates to methods of administering effective amounts of an anti-arrhythmic agent, e.g., dantrolene, azumolene or a pharmaceutically acceptable salt thereof, for the acute treatment of cardiac arrhythmias, e.g., atrial fibrillation, premature ventricular contraction, ventricular tachycardia or ventricular fibrillation, and prevention of subsequent cardiac arrhythmias, wherein the methods effectuate a reduction in morbidity and mortality.